1. This study aims to further elucidate the role of the tissue and plasma kallikrein-kinin systems in blood pressure, electrolyte and volume homoeostasis. Components thereof and of the renin-angiotensin-aldosterone system were measured in conjunction with frusemide administration, in normotensive subjects and in patients with primary hypertension.
INTRODUCTION
The protease kallikrein was described more than 50 years ago, and the functional organization of the kallikrein-kinin system is well known [l] . The end products of this system, kinins, have potent vasodilating and bloodpressure (BP)-lowering effects. As yet, the physiological roles of all of the components of the kallikrein-kinin system have not been clarified. For simplicity and perhaps also from functional aspects, the system has been divided into two separate entities, the tissue (glandular) and the plasma kallikrein-kinin systems. The plasma system is generally considered to participate in the activation of the intrinsic coagulation pathway, inflammation [2] and circulatory shock [3] . The tissue system probably plays a role in the excretory function and the regulation of local blood flow in different glands and the kidneys [4] , thereby participating in long-term BP regulation and eventually in the pathogenesis of hypertension [ 5 ] .
Tissue kallikrein (TK) circulates in blood [6] and can generate kinins in the bloodstream before it is inactivated [7] . Plasma pre-kallikrein (PK) is present in the circulation and can rapidly generate bradykinin after an activating stimulus [8] . It is therefore tempting to suggest a role for both circulating TK and plasma kallikrein in the enzymic generation of kinin and in the control of blood flow and BP homoeostasis. This has not been thoroughly investigated in man.
In order to investigate a potential role for circulating kallikreins in acute BP and volume regulation, we used a standardized frusemide administration test, which induces acute changes in volume and electrolyte status and potentially also in BP. Thus plasma levels of PK and T K and urinary excretion of T K were measured during a diagnostic renin-profiling procedure in patients with primary (essential) hypertension and in normotensive control subjects.
METHODS

Subjects and protocol
The patients included in the study had been referred for evaluation at the outpatient hypertension clinic of our University Hospital. Healthy, normotensive control subjects were recruited from the hospital staff and their friends. Twenty-seven patients (16 males, 11 females) with primary hypertension and 16 normal subjects (10 males, six females) were included in the study. All patients were previously untreated, except for one who had had antihypertensive medication withdrawn 1 1 months earlier. The essential hypertensive and normotensive groups were comparable except for body mass index, which was slightly higher in the hypertensive group (25.3 versus 23.5 kg/m2, P< 0.02). Further clinical characteristics are summarized in Table 1 . All subjects were on their normal diet with no Na+ restriction.
The subjects made three visits to the hypertension clinic. At the first visit BP was measured by two specially trained nurses and laboratory investigations were performed. At the second visit they were examined by one of us (K.P.O.), their BP was measured and further labortory investigations were performed. During the third visit a standardized renin-profiling procedure was performed by the nurses, as previously described [9] .
The laboratory routine blood testsincluded: haematological indices and serum levels of Na+, K', total Ca2+, CI-, phosphate, creatinine, urea, total protein, albumin, uric acid, bilirubin, liver enzymes, glucose, total and highdensity-lipoprotein cholesterol, and triacylglycerols. Urine tests included a dip-stick test for the presence of glucose, albumin and blood, urine osmolarity, and 24 h endogenous creatinine clearance. Blood and urine samples were collected in the morning after an overnight fast. Before each visit a 24 h urine collection was made and volume, creatinine, Na+, K + , C1-, Mg2+, aldosterone (ALDO), T K and prostaglandin E, (PGE,) contents were measured. An ECG was recorded, and if abnormal, was supplemented by a chest X-ray.
BP was measured with a mercury sphygmomanometer, with adjusted cuff size, and heart rate (HR) was determined by a pulse count for 30 s after 5 min of supine rest and 2 min of standing. Korotkoff phases I and V were used for the determination of systolic BP and diastolic BP, respectively.
Renin-profiling procedure
For the renin-profiling procedure, the subjects arrived in the out-patient clinic after an overnight fast. After voiding urine, BP, HR and weight were measured and blood was drawn for determination of plasma renin activity (PRA) and plasma concentrations of angiotensin I1 (ANG II), ALDO, PK and TK. Blood samples were drawn after the subject had been sitting for 5 min. Thereafter, frusemide (80 mg) was given orally. Urine was collected for 3 h, whereafter BP and HR measurements and blood sampling were repeated. The same analyses were performed on the 3 h urine specimens as on the 24 h urine collections. During the 3 h all subjects were ambulatory and were allowed to consume 200 ml of liquid (not coffee, tea or alcoholic beverages) and a sandwich.
Assay methods
Routine clinical laboratory methods were used for the blood and urine tests. Urine osmolarity was determined by the freezing point method. PRA was measured as generated angiotensin I, which was determined by r.i.a.
[lo], as were plasma ANG I1 concentration [ll] , plasma ALDO concentration [ 121, urinary ALDO concentration [13] , plasma TK concentration [14] and urinary PGE, concentration [ 151. Intra-and inter-assay coefficients of variation (CV,, and CV,,, respectively) were 5% and 9%, respectively, for TK using test plasma with a concentration of 4.75 pkat/l. CV,, was 3.9% for PRA and CV,, was 8.6%, 5.0% and 6.6% for test plasma with a concentration of 0.26, 1.60 and 2.70 pkat/l, respectively. CV,, was 10% for plasma ANG I1 concentration and CV,, was 10% and 14% for test plasma with a concentration of 15 and 54 pmol/l, respectively. CV, was 5.4% for plasma ALDO concentration and CV,, was 6.0% and 14% for test plasma with a concentration of 100 and 640 pmol/l, respectively. CV,, was 5% for urinary ALDO concentration and CV,, was 13% and 9% for test urine with a concentration of 2.19 and 66.7 nmol/l, respectively. CV,, and CV, for urinary PGE, concentration were 13% and 15%, respectively. Plasma PK and urinary T K concentrations were measured with chromogenic substrates S-2302 [16] and S-2266, respectively [17] . CV,, was 2% and CV,, was 5% for plasma PK concentration using a test plasma with a PK concentration of 89%. CV,, for urinary TK concentration was 2% and CV,, was 1 O%, 7% and 2% for test urine with a concentration of 2.58, 6.09 and 10.06 nkat/l, respectively.
Statistics
Standard statistical methods were used. Data are presented as mean sf^^^ and ranges, unless stated otherwise. Comparisons within and between groups were made by using Student's paired and unpaired two-tailed t-test, and Spearman's correlation test. Statistical significance was assumed at the 5% level.
RESULTS
BP and HR data on the day of frusemide administration are summarized in Table 2 . Supine and standing BPs and supine HR were significantly higher in the hypertensive patients than in the normotensive subjects at all measurements. At the second visit, when measured by the physician, systolic and diastolic BPs in the hypertensive patients and systolic BP in the normotensive subjects were slightly higher than the measurements made by a nurse at the first and third visits.
Three hours after frusemide administration, systolic and diastolic BPs in the hypertensive group were significantly lower than before and HR was higher in both the supine and standing positions, while in the normotensive subjects only supine and standing systolic BPs were lower and standing HR was increased.
There were no relevant abnormal findings in the blood and urine laboratory screening. Mean values for serum Na+, K+, Ca2+ (corrected for albumin concentration), creatinine, uric acid, glucose, high-density-lipoprotein cholesterol, and triacylglycerol levels did not differ quate urine collection) did not differ between the normotensive and hypertensive groups. Frusemide induced a diuresis and increased electrolyte excretion. The kallikrein excretion during the 3 h after frusemide administration was higher in normotensive subjects than in hypertensive patients (3.3 * 0.4 nkat/3 h and 1.9 5 0.2 nkat/3 h, respectively, P< 0.004), but the total volume and electrolyte, ALDO and PGE, excretion did not differ between the groups. The results were similar when expressed per mmol of creatinine, except that the difference between the two groups in TK excretion/mmol of creatinine did not achieve statistical significance ( P = 0.073). The urinary excretory data are listed in Table   4 . Urinary PGE, excretion per mmol of creatinine did not differ between males and females, and thus the data are not presented separately. For a comparison, Table 4 also shows the urinary concentration of the different excretory products, since kallikrein and PGE, might also exert effects on the tubular side of the epithelium. Also the urinary T K concentration was lower in hypertensive patients.
After frusemide administration, the amount of TK excreted in the urine (total and calculated per mmol of 
DISCUSSION
Kinins are very potent BP-lowering peptides, but whether they are actually circulating hormones and what their role in BP homoeostasis is are still much under debate [S] . Part of the confusion has been caused by technical problems in measuring true levels of kinins in blood [18] , although new methods have been developed which seem to measure the blood levels more appropriately. The development of kinin antagonists has supplied further evidence that kinins participate in BP regulation [19] . Whether kinins are generated by the plasma or the tissue kallikrein-kinin system has still to be elucidated.
The study was performed during a carefully standardized procedure that has been used in the clinical evaluation of hypertension in our laboratory for many years [9, 201. We measured plasma PK and TK levels in order to evaluate the possible involvement of the plasma and tissue kallikrein-kinin systems. The advantage of measuring the enzymes limiting the activity of the kallikrein-kinin systems and their precursors is that they are relatively stable and their measurement is easier and more reliable than that of the very rapidly generated and metabolized kinins. However, they do not actually show the final activity of the end products of the systems. Thus, any changes observed in the variables that we have studied may only indicate and not prove that the kallikrein-kinin systems are active in BP homoeostasis.
The activation of the plasma kallikrein-kinin system is a rapid chain reaction. In one step PK is activated to kallikrein by the activated Factor XI1 (XIIa) with the kallikrein-high-molecular-mass-kininogen complex as a cofactor. The extent of this reaction is determined by the amount of activated Factor XI, but not by acute formation or secretion of PK. We found an increase in the plasma PK level after the acute administration of frusemide. The increase was in excess of the haemoconcentration induced (average change in extravascular fluid + 2.6% and in serum albumin + 5.7' /0, n = 10). One might therefore speculate that in this acute experiment less PK is activated into kallikrein in the circulation, and subsequently less kinin is generated, since further vasodilatation induced by kinins might be deleterious during blood volume contraction induced by frusemide. The major source of circulating TK in humans is probably the kidney, but other organs may also contribute [21] . In the rat, the submandibular gland makes a significant contribution to the amount of circulating TK and it has been shown that the acute release of TK is accompanied by the generation of kinins before kallikrein is inactivated by circulating esterase inhibitors [7] . It is not known whether the same can occur in humans, but there are indications that the inactivation of kallikrein is slower in humans [22] and hence, kallikrein release may also rapidly generate kinins in humans. T K levels in plasma may in part be controlled by the rate of release. We found no change in circulating TK after frusemide administration, which is compatible with the observed reduced activation of plasma PK. Changes in circulating TK have been reported during long-term Na+ restriction [23] . This is similar to the effects of chronic administration of frusemide and other diuretics on urinary kallikrein excretion [24] . These stimuli induce secondary aldosteronism, which probably alters renal synthesis and release of kallikrein in the long term [2 1,251 .
Urinary kallikrein excretion is reduced in patients with primary hypertension [26] . However, this may be secondary to renal damage induced by the hypertensive state, since normal kallikrein excretion has also been reported in patients with mild hypertension [27] . The only sign of renal damage in the hypertensive patients in our study was a lower fasting morning urine osmolarity. We found lower mean values (but not statistically significant) of TK excretion in the hypertensive patients during each 24 h urinary collection period, regardless of whether the values were expressed as an absolute amount per mmol of creatinine or as a concentration. After frusemide administration the difference was statistically significant. This suggests a minor defect in renal kallikrein generation in the hypertensive patients. However, this defect does not seem to be relevant to acute renal excretory function since urine volume and electrolyte excretion did not differ between the groups.
The increase in kallikrein excretion induced by frusemide may be a wash-out effect, since it was only the amount that increased, while the concentration fell. This is also supported by experiments in the rat by Marks ef al. [28] and Bonner ef al. [29] , who postulated a tubular wash-out phenomenon as the basis for an early, but not total, increase in kallikrein excretion during diuresis induced by long-term blood volume expansion [28] or frusemide administration [29] . Still, even if the response to frusemide in the present study is a wash-out phenomenon, a lower excretion of kallikrein may be due to a reduced production, since the volume response was similar in the two groups.
Several studies on the effects of frusemide on urinary kallikrein and prostaglandins have also been performed in humans [24, 27, 301 . Stimulation of prostaglandins by frusemide appears to mediate increased renal blood flow [31] , but it has been difficult to link specific renal excretory effects of frusemide to either kallikrein or prostaglandins.
Urinary excretion of kallikrein was only found to correlate significantly with urinary K + and ALDO excretion in hypertensive patients after frusemide administration. This confirms early reports that urinary excretion of kallikrein is increased by mineralocorticoid agents [25, 321. Our results may indicate that the effects of mineralo-corticoids on the kallikrein-kinin system are more clearly expressed in hypertensive patients than in normotensive subjects. These differences are probably the result of differences in the long-term stimulatory action of mineralocorticoids on kallikrein levels and are not caused by acute changes in the renin-angiotensin-ALDO system induced by frusemide.
Determination of PRA is considered an indirect but reliable measure of plasma ANG I1 levels, as also documented in our laboratory in both normotensive subjects and hypertensive patients [33] . In the present study we only found a close relationship between PRA and plasma ANG I1 levels in the normotensive subjects, despite a lack of significant difference in absolute levels between the groups. The better distinction between the two groups in the present study may be because the sensitivity and specificity of the ANG I1 assay has been improved since our previous study. The present findings indicate a subtle dysregulation in the steps controlling PRA-ANG I1 relationships in mild (early) hypertension, and may also include more clearly expressed mineralocorticoid effects in hypertensive patients, as discussed above. However, we did not examine this further in this study.
In conclusion, we have found that the acute oral administration of frusemide not only stimulated the renin-angiotensin-ALDO system, but also increased plasma PK levels. This may indicate a functional involvement of the plasma kallikrein-kinin system in volume, electrolyte and BP homoeostasis. Circulating TK does not seem to be involved acutely. Frusemide-induced urinary excretion of kallikrein is reduced in patients with primary hypertension, but it does not correlate with any detectable functional abnormality in excretion.
